NoGainer1
Posted - 1 day ago
$CTMX $GLPG typische nbc-woche ;D
DonCorleone77
Posted - 1 day ago
$GLPG Galapagos presents new data from ATALANTA-1 study Galapagos announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma, or R/R NHL, at the annual European Hematology Association, or EHA, 2024 Hybrid Congress. Galapagos' product candidate GLPG5101 is produced using the company's innovative, decentralized T-cell manufacturing platform. The oral presentation includes updated safety and efficacy data for GLPG5101 in patients with diffuse large B-cell lymphoma, or DLBCL, follicular lymphoma, or FL, marginal zone lymphoma, or MZL, and mantle cell lymphoma, or MCL. The presentation also includes durability and cellular kinetics data. At the data cut-off date of December 20, 2023, no unexpected safety findings were observed and treatment with GLPG5101 resulted in high complete response rates in all indications in this heavily pretreated patient population. GLPG5101 was administered as a fresh product in 94% of patients with a median vein-to-vein time of seven days, eliminating the need for bridging therapy. T-cell subsets were assessed in the apheresis starting material and final CAR-T product. There was a higher proportion of early phenotypes of CD4+ and CD8+ CAR T cells in the final product compared with starting material, indicating an increase of those populations during the manufacturing process. This demonstrates the feasibility of Galapagos' decentralized manufacturing platform to deliver a high-quality CAR T-cell product to patients. As of the data cut-off date of December 20, 2023, 34 patients received GLPG5101 with a median vein-to-vein time of seven days. Overall, safety results were available for 33 patients and efficacy results were available for 31 patients. The data are summarized below: GLPG5101 showed an encouraging safety profile with most TEAEs1 of Grade 1 or 2; the majority of Grade = 3 events were hematological. Two cases of CRS2 Grade 3 were observed in Phase 1 and one case of ICANS3 Grade 3 was observed in Phase 2. In Phase 1, 14 of 16 efficacy-evaluable patients responded to treatment, with 12 patients achieving a complete response. In Phase 2, 14 of 15 efficacy-evaluable patients responded to treatment, and all responders achieved a complete response. High ORR and CRR were observed in the pooled Phase 1 and Phase 2 efficacy analysis set, split by indication: In patients with DLBCL, 7 of 9 efficacy-evaluable patients responded to treatment, with 5 patients achieving a complete response. In patients with FL or MZL, objective and complete responses were observed in 16 of 17 efficacy-evaluable patients. In patients with MCL, all 5 of 5 efficacy-evaluable patients responded to treatment. Durable responses were observed in the majority of responding patients: 71% of patients in Phase 1 had an ongoing response at data cut-off with median follow-up of 13.1 months. 100% of patients in Phase 2 had an ongoing response at data cut-off with median follow-up of 4.2 months. Strong and consistent in vivo CAR-T expansion levels and products consisting of early phenotype T cells were observed in all doses tested.
Aigner_Andreas
Posted - 4 days ago
#TrendFollowing #TOP10 WK 24 SELL US $SIRI $GLPG $IEX $GPRO $PXLW NICE FIVN MED MRSN IOVA
psychohaiko
Posted - 5 days ago
$GLPG Dr. Jens Löwe bitte in den OP - ihr Patient verblutet... #NoAbo @ german shitdeals
Wicktory
Posted - 5 days ago
$GLPG When will they run out of money?
Fingerlickengood
Posted - 6 days ago
$GLPG $ADAP Interesting that EcoR1 has very significant investments in ‘both’ Galapagos and Adamptimmune
Fingerlickengood
Posted - 1 week ago
$ADAP $GLPG …is this potentially a game changer? Autologous Cell Therapies Hit Their Stride in Solid Tumors May 30, 2024 ”According to Norry, Adaptimmune is conducting preclinical work looking for a peptide MHC for MAGE-A4 for patients with other HLA types. There are hundreds of HLA types in the global population, but Norry said his firm believes that if they can engineer their therapy for four different HLA types, it can reach up to 80 percent of the world's population. "It is our absolute desire to move beyond just HLA-A*02," he said. ” https://www.precisionmedicineonline.com/precision-oncology/autologous-cell-therapies-hit-their-stride-solid-tumors
PhaseHaiko
Posted - 1 week ago
$GLPG EUER HAIKO @Hailight
dhovekamp42
Posted - 1 week ago
@Morts0b $ADAP gets $85m (upfront $70m exclusivity + $15m R&D) from $GLPG + another $15m R&D with start of uza-cel dosing in proof-of-concept study in H&N - guidance on cash reach with next earnings
Fingerlickengood
Posted - 1 week ago
$ADAP Small daily gains into PDUFA $GLPG
Fingerlickengood
Posted - 1 week ago
$ADAP See you Monday! $IOVA $GLPG $GILD
tradingtwenty
Posted - 05/31/24
$GLPG $ADAP has trended 39 times in the past 24 hours (based on 5 minute intervals). Latest press release on May 30, 2024 04:01 PM: Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License... Link: https://tradingtwenty.com/news/493323/adaptimmune-and-galapagos-sign-clinical-collaboration-agreement-with-an-option-to-exclusively-license-adaptimmunes-tcr-t-cell-therapy-candidate-uza-cel-in-head--neck-cancer-and-potential-future-solid-tumor-indications
OpenOutcrier
Posted - 05/31/24
$ADAP (+21.8% pre) Adaptimmune and $GLPG Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate - SI https://ooc.bz/l/34315
Bionco
Posted - 05/31/24
$ADAP I think $GLPG will eventually acquire ADAP. Let's see when it will happen!
dhovekamp42
Posted - 05/30/24
@MoonLanding86 to the moon if $GLPG pulls the buy trigger
Bionco
Posted - 05/30/24
@dhovekamp42 @BradLoncar it looks like $GLPG has already collaborated with $ADAP for not a short time since they already produced some Initial in vitro data
dhovekamp42
Posted - 05/30/24
$ADAP must watch! nice early speculation on matched interests in this $GLPG BioTechTV interview with @BradLoncar by Dimitri Kovalchuk https://x.com/DmitryKovalchuk/status/1745369527620112599
Fingerlickengood
Posted - 05/30/24
$ADAP $LZAGF $GLPG So Lonza Group will have a stake in the commercialization?!
Fingerlickengood
Posted - 05/30/24
$GLPG I can't be certain here, but for Galopagos to sign off on commercialization and such large lump sums of cash infusion while uza-cel has only completed Phase I clinical trails, suggests to me they have the 'head-nod' already from the FDA to use this special designation to rush it into commercialization!
dhovekamp42
Posted - 05/30/24
@Fingerlickengood @Apr4609 currently $GLPG exclusivity only in H&N cancer and option to more while $ADAP gains access to GLPG distributed manufacturing (!)
DonCorleone77
Posted - 05/30/24
$GLPG $ADAP Galapagos and Adaptimmune in clinical collaboration agreement for uza-cel Galapagos (GLPG) and Adaptimmune Therapeutics ( ADAP) announced that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy uza-cel, targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform. The Adaptimmune sponsored Phase 1 SURPASS trial with centrally manufactured uza-cel has shown encouraging results in head & neck cancer with an overall response rate of 80%. Initial in vitro results suggest that uza-cel, produced on Galapagos' decentralized manufacturing platform, yields early phenotype T-cells that could improve efficacy and durability compared to uza-cel centrally manufactured on Adaptimmune's platform.2 In addition, Galapagos' decentralized manufacturing platform offers the potential for the delivery of fresh, fit cells with a vein-to-vein time of seven days in a patient population in which rapid access to treatment is vital.